Department of Neurology, Technische Universität München, München, Germany.
Division of Rheumatology, McGill University Health Centre, Montreal, Quebec, Canada.
Eur J Pain. 2021 Jul;25(6):1195-1208. doi: 10.1002/ejp.1742. Epub 2021 Feb 28.
The many risks associated with opioid therapy for chronic non-cancer pain (CNCP) have led to questions about use. This is particularly relevant for risk of increased mortality. However, underlying medical conditions of those using opioids may influence mortality findings due to confounding by indication. Similarly, non-opioid analgesics are also associated with an increased risk of mortality, too.
We have conducted a systematic review of propensity score matched observational studies comparing mortality associated with opioid use compared to non-opioid analgesics. Clinicaltrials.gov, Google Scholar, MEDLINE and Scopus were searched from inception to July 2020. Propensity score matched observational studies comparing opioids to non-opioid analgesics in real-world settings were analysed. Primary outcome was pooled adjusted hazard ratio (aHR) of all-cause death. Effects were summarized by a random effects model.
Four studies with seven study arms and 120,186 patients were analysed. Pooled aHR for all-cause death was 1.69 (95% confidence interval [CI] 1.47, 1.95). When mortality risk was confined to out-of-hospital deaths, the pooled aHR was 2.12 (95% CI 1.46, 3.09). The most frequent cause of death was cardiovascular death. Before matching, patients with opioids were older and had more somatic diseases than patients with non-opioids. Despite extensive propensity score matchings and sensitivity analyses, all studies could not fully exclude confounding by indication.
Possibly, opioids are associated with an increased all-cause mortality risk compared to non-opioid analgesics. When considering treatment options for patients with CNCP, the possible risk of increased all-cause mortality with opioids should be discussed.
An increased all-cause mortality associated with opioid use compared to non-opioid analgesics for CNCP was identified by a systematic review of four propensity score matched cohort studies in real-world settings. The number needed to harm for an additional excess death per 10,000 person-years was 116. Despite extensive propensity score matchings and sensitivity analyses, all studies could not fully exclude confounding by indication. The potential risk of increased all-cause mortality with opioids should be discussed with patients when considering opioid treatment.
阿片类药物治疗慢性非癌性疼痛(CNCP)存在诸多风险,这引发了人们对其使用的质疑。这在死亡率风险方面尤为明显。然而,由于指示性混杂,使用阿片类药物的患者的基础疾病可能会影响死亡率的发现。同样,非阿片类镇痛药也与死亡率增加有关。
我们对比较阿片类药物与非阿片类镇痛药相关死亡率的倾向评分匹配观察性研究进行了系统回顾。从创建到 2020 年 7 月,在 Clinicaltrials.gov、Google Scholar、MEDLINE 和 Scopus 上进行了检索。分析了在真实环境中比较阿片类药物与非阿片类镇痛药的倾向评分匹配观察性研究。主要结局是全因死亡的汇总调整后的危害比(aHR)。采用随机效应模型对结果进行总结。
纳入了 4 项研究共 7 个研究臂和 120186 名患者。全因死亡的汇总 aHR 为 1.69(95%置信区间[CI] 1.47,1.95)。当将死亡率风险限于院外死亡时,汇总 aHR 为 2.12(95%CI 1.46,3.09)。最常见的死亡原因是心血管死亡。在匹配之前,阿片类药物组的患者比非阿片类药物组的患者年龄更大且患有更多的躯体疾病。尽管进行了广泛的倾向评分匹配和敏感性分析,但所有研究都不能完全排除指示性混杂。
与非阿片类镇痛药相比,阿片类药物可能与全因死亡率增加相关。在为 CNCP 患者考虑治疗方案时,应讨论阿片类药物治疗可能增加的全因死亡率风险。
通过对四项真实环境中倾向评分匹配队列研究的系统回顾,发现与非阿片类镇痛药相比,阿片类药物治疗慢性非癌性疼痛的全因死亡率增加。每 10000 人年额外死亡 116 例的危害人数需要数。尽管进行了广泛的倾向评分匹配和敏感性分析,但所有研究都不能完全排除指示性混杂。在考虑阿片类药物治疗时,应与患者讨论阿片类药物治疗全因死亡率增加的潜在风险。